Skip to main content
. 2019 Dec 8;182(6):1369–1378. doi: 10.1111/bjd.18552

Figure 3.

Figure 3

Objective response rates by central review across all BOLT (Basal Cell Carcinoma Outcomes with LDE225 Treatment) analyses in patients receiving sonidegib 200 mg daily.17, 19, 20 Results are for the intent‐to‐treat population. BCC, basal cell carcinoma; laBCC, locally advanced BCC; mBCC, metastatic BCC; ORR, objective response rate.